Abstract Session 2: Biology

Co-Chair(s)

• 

  Annemiek Broijl, MD, PhD (she/her/hers)

  Hematologist
  ErasmusMC
  Rotterdam, Zuid-Holland, Netherlands
• 

  Lugui Qiu, MD (he/him/his)

  Department Head
  Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  Tianjin , China (People's Republic)

Presentations:

• 5:45 PM – 5:57 PM EEST

  OA-35: High-throughput plasma proteomics to define the precursor multiple myeloma proteome and identify candidate high-risk disease biomarkers of progression
  

  Speaker: Elizabeth D. Lightbody, PhD – Dana-Farber Cancer Institute
• 5:57 PM – 6:09 PM EEST

  OA-21: Dysregulated APOBEC3B promotes cell proliferation and DNA damage in multiple myeloma
  

  Speaker: Afsaneh Panahi, MSc – BC Cancer Research Centre/ University of British Columbia
• 6:09 PM – 6:21 PM EEST

  OA-36: sBCMA predicts progression and is a biomarker of response in myeloma precursor disease followed on prospective studies
  

  Speaker: wei tan, Ph.D – The University of Texas MD Anderson Cancer Center
• 6:21 PM – 6:33 PM EEST

  OA-15: Serial MRD Assessments as a Surrogate for Long Term Progression Free Survival
  

  Speaker: Frits van Rhee, MD PHD (he/him/his) – Myeloma Center, University of Arkansas of Medicine
• 6:33 PM – 6:45 PM EEST

  OA-30: Critical roles of CRIP1 in promoting cell survival and bortezomib resistance by enhancing proteasome activity and autophagy in multiple myeloma
  

  Speaker: Hao Mu, Principle Investigation (she/her/hers) – State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.